×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism
By
L&C BIO Co., Ltd
L&C BIO Co., Ltd
03 Dec 2025
Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).
By
Celltrion
Celltrion
01 Dec 2025
Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe
By
Samsung Bioepis Co., Ltd.
Samsung Bioepis Co., Ltd.
01 Dec 2025
Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)
By
Menarini Industrie Farmaceutiche Riunite
Menarini Industrie Farmaceutiche Riunite
25 Nov 2025
Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.
By
Eisai Inc.
Eisai Inc.
25 Nov 2025
VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction
By
Intuitive Ventures
Intuitive Ventures
19 Nov 2025
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
Onco360 now offers LAZCLUZE™ (lazertinib) with Rybrevant® for first-line treatment of metastatic non-small cell lung cancer with specific EGFR mutations
By
Onco360 Oncology Pharmacy
Aug 30
NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price
By
Kadimastem Ltd.; NLS Pharmaceutics Ltd.
Jan 08
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
By
AbbVie
Jun 27
January
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe for e-Newsletter Monthly
Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
Email
I consent to subscribing to the selected email lists.
Enter the code below
Subscribe
1
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand
